ライフサイエンスコーパス: HIV envelope protein

1 n active humoral immune response against the HIV envelope protein.

2 rom volunteers vaccinated with a recombinant HIV envelope protein.

3 luding mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120.

4 constructs expressing one of three different HIV envelope proteins, after which the CD4(+) T cell res

5 Despite binding HIV envelope protein and having a high number of somatic

6 structure, function, and antigenicity of the HIV envelope protein and represents a new approach to th

7 Immunotoxins (ITs) targeting the HIV envelope protein are among the most efficacious anti

8 of the primary receptor in complex with the HIV envelope protein as compared to the binding observed

9 ometry-based sorting of single B cells using HIV envelope protein baits.

10 imilar to MAdCAM, the V2 domain of the gp120 HIV envelope protein binds to alpha(4)beta(7) In this st

11 izing anti-HIV antibodies (bNAbs) binding to HIV envelope protein capably block cell-free virus sprea

12 These studies indicate that the HCV/HIV envelope proteins cooperatively induce hepatocytic a

13 ies to the third variable region (V3) of the HIV envelope protein correlate with reduced HIV infectio

14 macaques show that boosting with a specific HIV envelope protein does not significantly boost antibo

15 major targets on the gp120 component of the HIV envelope protein (Env) for broadly neutralizing anti

16 ponses to specific neutralizing sites on the HIV envelope protein (Env) trimer or on other pathogens.

17 surface, we sought to determine whether the HIV envelope protein (Env) was genotypically and phenoty

18 e responses to human immunodeficiency virus (HIV) envelope protein (Env) expressed by replication-com

19 A mutant human immunodeficiency virus (HIV) envelope protein (Env) with an engineered disulfide

20 ressed either the unmodified or the chimeric HIV envelope protein formed syncytia with cells expressi

21 replicon particle (VRP) or by a recombinant HIV envelope protein formulated with MF59 adjuvant, anti

22 e same primary human immunodeficiency virus (HIV) envelope protein, gave a fourfold increase in antib

23 The HIV envelope proteins glycoprotein 120 (gp120) and glyco

24 SP-D has been shown to bind to HIV via the HIV envelope protein gp120 and inhibit infectivity in vi

25 HIV envelope protein gp120 exerts axonal toxicity direct

26 binding of CV-N to the heavily glycosylated HIV envelope protein gp120 is carbohydrate-dependent.

27 To initiate HIV entry, the HIV envelope protein gp120 must engage its primary recep

28 We have shown that the HIV envelope protein gp120 promotes loss of synapses and

29 otective in vitro against two strains of the HIV envelope protein gp120 that binds to CXCR4 or CCR5.

30 act as inhibitors to prevent the binding of HIV envelope protein gp120 to DC-SIGN at nanomolar conce

31 are recognized by 2G12 as tightly as is the HIV envelope protein gp120, and they are the first const

32 ding network of a recombinant monomer of the HIV envelope protein gp120.

33 ype and p53 deficient mice to the neurotoxic HIV envelope protein gp120.

34 ls via anti-CD4 antibody or immune-complexed HIV envelope protein gp120.

35 tic agents dichloroacetate and paclitaxel or HIV envelope protein gp120.

36 body (MoAb) or human immunodeficiency virus (HIV) envelope protein gp120 reduces the expression of th

37 In this study, a complex of the HIV-envelope protein gp120 and its cellular receptor CD4

38 This study demonstrates that the HIV envelope protein, gp120, activates human arterial sm

39 tive ligands, MIP-1beta/SDF-1alpha or by the HIV envelope protein, gp120.

40 okines in the spinal cord induced by a major HIV-envelope protein, gp120.

41 -3 LCs and in this form preferentially bound HIV envelope protein gp140 and whole HIV particles via t

42 al blood of HIV-negative healthy donors with HIV envelope protein gp160 alone or performed CD4XL with

43 (HIV)-infected individuals, the level of the HIV envelope protein gp41 in brain tissue is correlated

44 ragment encompassing residues 282-304 of the HIV envelope protein gp41 is studied when solubilized by

45 inding to the glycosylated ectodomain of the HIV-envelope protein gp41 (sgp41) (as well as SIV glycop

46 iscontinuous epitope in the C5 region of the HIV envelope protein HIV-gp120, recognized by 1331A, a h

47 The incorporation of the chimeric HIV envelope protein into the membrane of the recombinan

48 C5 structure lends insight into the site of HIV envelope protein maturation by the host enzymes furi

49 ace receptors on NK cells that interact with HIV envelope proteins might explain how HIV is capable o

50 expressing the human immunodeficiency virus (HIV) envelope protein or an HIV-VSV chimeric envelope pr

51 Glycans on human immunodeficiency virus (HIV) envelope protein play an important role in infectio

52 shield of the human immunodeficiency virus (HIV) envelope protein presents many potential epitopes f

53 ata demonstrate that exposure of NK cells to HIV envelope proteins results in profound cellular abnor

54 d allows users to analyze that data for each HIV Envelope protein sequence position and each antibody

55 icantly higher CD4+ T-cell response rates to HIV envelope protein than administration by needle/syrin

56 ER) of the gp41-transmembrane subunit of the HIV envelope protein, that is recognized by several well

57 oups are developing immunogens, based on the HIV envelope protein, that require complex and lengthy i

58 ral studies of human immunodeficiency virus (HIV) envelope proteins, the loop region of gp41 is thoug

59 in HIV-infected subjects is mediated by the HIV envelope protein through the CXCR4 chemokine recepto

60 e applied cellPACK to model distributions of HIV envelope protein to test several hypotheses for cons

61 e, we used IgA monoclonal antibodies against HIV envelope proteins to investigate the abilities of po

62 y showed that hepatocytes exposed to HCV and HIV envelope proteins undergo apoptosis via an innocent-

63 Nonglycosylated HIV envelope protein was not associated with calreticuli

64 otein in which the cytoplasmic domain of the HIV envelope protein was replaced with that from the VSV

65 with deletions in early genes and expressing HIV envelope protein was shown to induce greater HIV-spe

66 ress a chimeric B5R-HIV protein or a control HIV envelope protein with the original cytoplasmic and t

67 nd microscopic studies demonstrated that the HIV envelope proteins with the B5R cytoplasmic and trans